Distinct roles for cysteine cathepsin genes in multistage tumorigenesis

Genes and Development

Volumn 20, Issue 5, 2006, Pages 543-556

  Gocheva, Vasilena ^a,b   Zeng, Wei ^a   Ke, Danxia ^a   Klimstra, David ^a   Reinheckel, Thomas ^c   Peters, Christoph ^c   Hanahan, Douglas ^d   Joyce, Johanna A ^a,d  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Weill Cornell Graduate School of Biomedical Sciences   (United States)

^c UNIVERSITY OF FREIBURG   (Germany)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cancer; Cysteine cathepsins; Mouse models; Pancreatic endocrine cancer; Proteases; Tumor microenvironment

Indexed keywords

CATHEPSIN B; CATHEPSIN L; CATHEPSIN S; CYSTEINE PROTEINASE; DIPEPTIDYL PEPTIDASE I; UVOMORULIN;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER INVASION; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE COURSE; ENDOCRINE TUMOR; ENZYME SUBSTRATE; GENE MUTATION; KNOCKOUT GENE; MALIGNANT NEOPLASTIC DISEASE; MOUSE; NONHUMAN; NULL ALLELE; PANCREAS TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; TUMOR GROWTH; TUMOR VASCULARIZATION;

ANIMALS; APOPTOSIS; CADHERINS; CATHEPSINS; CELL PROLIFERATION; CROSSES, GENETIC; CYSTEINE PROTEINASE INHIBITORS; ENZYME ACTIVATION; FLUORESCEIN-5-ISOTHIOCYANATE; FLUORESCENT DYES; HUMANS; IMMUNOHISTOCHEMISTRY; INDOLES; MICE; MICE, CONGENIC; MICE, INBRED C57BL; MICE, INBRED STRAINS; MICE, KNOCKOUT; MUTATION; NEOPLASM INVASIVENESS; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; PANCREATIC NEOPLASMS; RECOMBINANT PROTEINS; TUMOR BURDEN; UP-REGULATION;

ANIMALIA;

EID: 33644784910     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.1407406     Document Type: Article

References (48)

1. Balaji, K.N., Schaschke, N., Machleidt, W., Catalfamo, M., and Henkart, P.A. 2002. Surface cathepsin B protects cytotoxic lymphocytes from self-destruction after degranulation. J. Exp. Med. 196: 493-503.
2. Beavon, I.R. 2000. The E-cadherin-catenin complex in tumour metastasis: Structure, function and regulation. Eur. J. Cancer 36 (13 Spec No): 1607-1620.
3. Bergers, G., Song, S., Meyer-Morse, N., Bergsland, E., and Hanahan, D. 2003. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Invest. 111: 1287-1295.
4. Camp, R.L., Charette, L.A., and Rimm, D.L. 2000. Validation of tissue microarray technology in breast carcinoma. Lab. Invest. 80: 1943-1949.
5. Cavallaro, U. and Christofori, G. 2004. Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat. Rev. Cancer 4: 118-132.
6. Cupisti, K., Hoppner, W., Dotzenrath, C., Simon, D., Berndt, I., Roher, H.D., and Goretzki, P.E. 2000. Lack of MEN1 gene mutations in 27 sporadic insulinomas. Eur. J. Clin. Invest. 30: 325-329.
7. Felbor, U., Kessler, B., Mothes, W., Goebel, H.H., Ploegh, H.L., Bronson, R.T., and Olsen, B.R. 2002. Neuronal loss and brain atrophy in mice lacking cathepsins B and L. Proc. Natl. Acad. Sci. 99: 7883-7888.
8. Folkman, J., Watson, K., Ingber, D., and Hanahan, D. 1989. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339: 58-61.
9. Goulet, B., Baruch, A., Moon, N.S., Poirier, M., Sansregret, L.L., Erickson, A., Bogyo, M., and Nepveu, A. 2004. A cathepsin L isoform that is devoid of a signal peptide localizes to the nucleus in S phase and processes the CDP/Cux transcription factor. Mol. Cell 14: 207-219.
10. Guicciardi, M.E., Miyoshi, H., Bronk, S.F., and Gores, G.J. 2001. Cathepsin B knockout mice are resistant to tumor necrosis factor-α- mediated hepatocyte apoptosis and liver injury: Implications for therapeutic applications. Am. J. Pathol. 159: 2045-2054.
11. Halangk, W., Lerch, M.M., Brandt-Nedelev, B., Roth, W., Ruthenbuerger, M., Reinheckel, T., Domschke, W., Lippert, H., Peters, C., and Deussing, J. 2000. Role of cathepsin B in intracellular trypsinogen activation and the onset of acute pancreatitis. J. Clin. Invest. 106: 773-781.
12. Hanahan, D. 1985. Heritable formation of pancreatic β-cell tumours in transgenic mice expressing recombinant insulin/ simian virus 40 oncogenes. Nature 315: 115-122.
13. Hochwald, S.N., Zee, S., Conlon, K.C., Colleoni, R., Louie, O., Brennan, M.F., and Klimstra, D.S. 2002. Prognostic factors in pancreatic endocrine neoplasms: An analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J. Clin. Oncol. 20: 2633-2642.
14. Inoue, M., Hager, J.H., Ferrara, N., Gerber, H.P., and Hanahan, D. 2002. VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic β cell carcinogenesis. Cancer Cell 1: 193-202.
15. Jedeszko, C. and Sloane, B.F. 2004. Cysteine cathepsins in human cancer. Biol. Chem. 385: 1017-1027.
16. Jonkers, Y.M., Claessen, S.M., Perren, A., Schmid, S., Komminoth, P., Verhofstad, A.A., Hofland, L.J., de Krijger, R.R., Slootweg, P.J., Ramaekers, F.C., et al. 2005. Chromosomal instability predicts metastatic disease in patients with insulinomas. Endocr. Relat. Cancer 12: 435-447.
17. Joyce, J.A. and Hanahan, D. 2004. Multiple roles for cysteine cathepsins in cancer. Cell Cycle 3: 1516-1519.
18. Joyce, J.A., Baruch, A., Chehade, K., Meyer-Morse, N., Giraudo, E., Tsai, F.Y., Greenbaum, D.C., Hager, J.H., Bogyo, M., and Hanahan, D. 2004. Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell 5: 443-453.
19. Joyce, J.A., Freeman, C., Meyer-Morse, N., Parish, C.R., and Hanahan, D. 2005. A functional heparan sulfate mimetic implicates both heparanase and heparan sulfate in tumor angiogenesis and invasion in a mouse model of multistage cancer. Oncogene 24: 4037-4051.
20. Kerbel, R. and Folkman, J. 2002. Clinical translation of angiogenesis inhibitors. Nat. Rev. Cancer 2: 727-739.
21. Lochter, A., Galosy, S., Muschler, J., Freedman, N., Werb, Z., and Bissell, M.J. 1997. Matrix metalloproteinase stromelysin-1 triggers a cascade of molecular alterations that leads to stable epithelial-to-mesenchymal conversion and a premalignant phenotype in mammary epithelial cells. J. Cell Biol. 139: 1861-1872.
22. Lopez, T. and Hanahan, D. 2002. Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis. Cancer Cell 1: 339-353.
23. Mai, J., Finley Jr., R.L., Waisman, D.M., and Sloane, B.F. 2000. Human procathepsin B interacts with the annexin II tetramer on the surface of tumor cells. J. Biol. Chem. 275:12806-12812.
24. Mantel, N. 1963. Chi-square tests with one degree of freedom: Extensions of the Mantel-Haenszel procedure. J. Am. Stat. Assoc. 58: 690-700.
25. Maretzky, T., Reiss, K., Ludwig, A., Buchholz, J., Scholz, F., Proksch, E., de Strooper, B., Hartmann, D., and Saftig, P. 2005. ADAM10 mediates E-cadherin shedding and regulates epithelial cell-cell adhesion, migration, and β-catenin translocation. Proc. Natl. Acad. Sci. 102: 9182-9187.
26. McCullagh, P. 1980. Regression models for ordinal data. J. Roy. Stat. Soc. B 42: 109-142.
27. Mort, J.S., Recklies, A.D., and Poole, A.R. 1985. Release of cathepsin B precursors from human and murine tumours. Prog. Clin. Biol. Res. 180: 243-245.
28. Noe, V., Chastre, E., Bruyneel, E., Gespach, C., and Mareel, M. 1999. Extracellular regulation of cancer invasion: The E-cadherin -catenin and other pathways. Biochem. Soc. Symp. 65: 43-62.
29. Noe, V., Fingleton, B., Jacobs, K., Crawford, H.C., Vermeulen, S., Steelant, W., Bruyneel, E., Matrisian, L.M., and Mareel, M. 2001. Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. J. Cell Sci. 114: 111-118.
30. Perl, A.K., Wilgenbus, P., Dahl, U., Semb, H., and Christofori, G. 1998. A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature 392: 190-193.
31. Pham, C.T. and Ley, T.J. 1999. Dipeptidyl peptidase I is required for the processing and activation of granzymes A and B in vivo. Proc. Natl. Acad. Sci. 96: 8627-8632.
32. Rao, J.S. 2003. Molecular mechanisms of glioma invasiveness: The role of proteases. Nat. Rev. Cancer 3: 489-501.
33. Reinheckel, T., Deussing, J., Roth, W., and Peters, C. 2001. Towards specific functions of lysosomal cysteine peptidases: Phenotypes of mice deficient for cathepsin B or cathepsin L. Biol. Chem. 382: 735-741.
34. Roth, W., Deussing, J., Botchkarev, V.A., Pauly-Evers, M., Saftig, P., Hafner, A., Schmidt, P., Schmahl, W., Scherer, J., Anton-Lamprecht, I., et al. 2000. Cathepsin L deficiency as molecular defect of furless: Hyperproliferation of keratinocytes and perturbation of hair follicle cycling. FASEB J. 14: 2075-2086.
35. Ryniers, F., Stove, C., Goethals, M., Brackenier, L., Noe, V., Bracke, M., Vandekerckhove, J., Mareel, M., and Bruyneel, E. 2002. Plasmin produces an E-cadherin fragment that stimulates cancer cell invasion. Biol. Chem. 383: 159-165.
36. Saftig, P., Hunziker, E., Wehmeyer, O., Jones, S., Boyde, A., Rommerskirch, W., Moritz, J.D., Schu, P., and von Figura, K. 1998. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc. Natl. Acad. Sci. 95: 13453-13458.
37. Shan, L., Nakamura, Y., Nakamura, M., Yokoi, T., Tsujimoto, M., Arima, R., Kameya, T., and Kakudo, K. 1998. Somatic mutations of multiple endocrine neoplasia type 1 gene in the sporadic endocrine tumors. Lab. Invest. 78: 471-475.
38. Shi, G.P., Villadangos, J.A., Dranoff, G., Small, C., Gu, L., Haley, K.J., Riese, R., Ploegh, H.L., and Chapman, H.A. 1999. Cathepsin S required for normal MHC class II peptide loading and germinal center development. Immunity 10: 197-206.
39. Simon, R. and Sauter, G. 2003. Tissue microarray (TMA) applications: Implications for molecular medicine. Expert Rev. Mol. Med. 2003: 1-12.
40. Stypmann, J., Glaser, K., Roth, W., Tobin, D.J., Petermann, I., Matthias, R., Monnig, G., Haverkamp, W., Breithardt, G., Schmahl, W., et al. 2002. Dilated cardiomyopathy in mice deficient for the lysosomal cysteine peptidase cathepsin L. Proc. Natl. Acad. Sci. 99: 6234-6239.
41. Turk, V., Turk, B., and Turk, D. 2001. Lysosomal cysteine proteases: Facts and opportunities. EMBO J. 20: 4629-4633.
42. Turk, B., Stoka, V., Rozman-Pungercar, J., Cirman, T., Droga-Mazovec, G., Oresic, K., and Turk, V. 2002. Apoptotic pathways: Involvement of lysosomal proteases. Biol. Chem. 383: 1035-1044.
43. Turk, V., Turk, B., Guncar, G., Turk, D., and Kos, J. 2002. Lysosomal cathepsins: Structure, role in antigen processing and presentation, and cancer. Adv. Enzyme Regul. 42: 285-303.
44. Viola, K.V. and Sosa, J.A. 2005. Current advances in the diagnosis and treatment of pancreatic endocrine tumors. Curr. Opin. Oncol. 17: 24-27.
45. Vleminckx, K., Vakaet Jr., L., Mareel, M., Fiers, W., and van Roy, F. 1991. Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell 66: 107-119.
46. Wang, B., Sun, J., Kitamoto, S., Yang, M., Grubb, A., Chapman, H.A., Kalluri, R., and Shi, G.P. 2006. Cathepsin S controls angiogenesis and tumor growth via matrix-derived angiogenic factors. J. Biol. Chem. (in press).
47. Yasothornsrikul, S., Greenbaum, D., Medzihradszky, K.F., Toneff, T., Bundey, R., Miller, R., Schilling, B., Petermann, I., Dehnert, J., Logvinova, A., et al. 2003. Cathepsin L in secretory vesicles functions as a prohormone-processing enzyme for production of the enkephalin peptide neurotransmitter. Proc. Natl. Acad. Sci. 100: 9590-9595.
48. Zhuang, Z., Vortmeyer, A.O., Pack, S., Huang, S., Pham, T.A., Wang, C., Park, W.S., Agarwal, S.K., Debelenko, L.V., Kester, M., et al. 1997. Somatic mutations of the MEN1 tumor suppressor gene in sporadic gastrinomas and insulinomas. Cancer Res. 57: 4682-4686.